Author

Fei Jie

Observed name: Fei JIE

Observed institutions: Pfizer (United States), Astellas Pharma (United States)

OpenAlex ID: A5108644696

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

2014 · Michael R. Clemens, Oleg A. Gladkov, et al. · Breast Cancer Research and Treatment · 79

PDF

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

2016 · Joaquin Mateo, David Olmos, et al. · British Journal of Cancer · 67

PDF

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

2025 · Nancy L. Bartlett, Uwe Hahn, et al. · Journal of Clinical Oncology · 49

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

2016 · Helena Alexandra Yu, Alexander I. Spira, et al. · Journal of Clinical Oncology · 28

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

2017 · Helena A. Yu, Alexander Spira, et al. · Clinical Cancer Research · 27

PDF

Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).

2020 · Wungki Park, Eileen Mary O'Reilly, et al. · Journal of Clinical Oncology · 8

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.

2024 · Jeong A Kim, Uwe Hahn, et al. · Journal of Clinical Oncology · 5

PDF

A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.

2012 · Joyce Leta Steinberg, Agop Y. Bedikian, et al. · Journal of Clinical Oncology · 4

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

2025 · Nancy L. Bartlett, Uwe Hahn, et al. · Future Oncology · 2

PDF

Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.

2013 · Joaquin Mateo, Patrick Schoffski, et al. · Molecular Cancer Therapeutics · 1

Ten-year Follow-up of Echelon-1: Overall Survival and Long-term Safety With Brentuximab Vedotin Plus Avd Versus Abvd in Patients With Previously Untreated Advanced Classic Hodgkin Lymphoma

2026 · Adriana SCHELIGA, Stephen ANSELL, et al. · Hematology Transfusion and Cell Therapy

Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States

2026 · Michael Wallington, Yong Chen, et al. · Journal of Clinical Medicine

Msr118 Assessing the Impact of Inclusion of Patients With Missing Eastern Cooperative Oncology Group (ecog) Performance Status in Real-world Outcomes of Third-line or Later (3l+) Diffuse Large B-cell Lymphoma (dlbcl)

2026 · Michael Wallington, Yong Chen, et al. · Value in Health

SA42 Feasibility Assessment of a Real-World Comparator Cohort Using Multiple Qualifying Index Lines of Therapy (LOTs) in Third-Line or Later (3L+) Diffuse Large B-cell Lymphoma (DLBCL)

2025 · Michael Wallington, Yong Chen, et al. · Value in Health

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

2025 · Michael Wallington, Yong Chen, et al. · Blood

PDF

Safety characteristics of brentuximab vedotin among patient subgroups: Insightsfrom pooled clinical trial database

2025 · Heather Ward, Wamiq Zaidi, et al. · Blood

Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

2024 · Christopher Yasenchak, Jeong-A Kim, et al. · Clinical Lymphoma Myeloma & Leukemia

ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

2024 · Christopher Yasenchak, Jeong-AA Kim, et al. · Clinical Lymphoma Myeloma & Leukemia

Supplementary Table 1, Supplementary Figures 1-4 from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

2023 · Helena A. Yu, Alexander Spira, et al.

Data from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

2023 · Helena A. Yu, Alexander Spira, et al.

Data from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

2023 · Helena A. Yu, Alexander Spira, et al.

Abstract A47: Clinical profile of ASP8273, a mutant-selective EGFR inhibitor, in subjects with EGFR-mutation positive non-small cell lung cancer: interim results from an ongoing, phase 1, open-label, dose-escalation study

2015 · Helena Yu, Geoffrey R. Oxnard, et al. · Molecular Cancer Therapeutics

Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer.

2013 · Michael R. Clemens, Anne Therese Keating, et al. · Journal of Clinical Oncology

Works count: 24

Citation count: 270

H-index: 6

I10-index: 5